Ischemic Stroke: Treatment on the horizon

European Neurology

Volumn 36, Issue 2, 1996, Pages 61-64

  Giroux, Christian ^a   Scatton, Bernard ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; APTIGANEL; CALCIUM CHANNEL BLOCKING AGENT; DEXTROMETHORPHAN; DEXTRORPHAN; ELIPRODIL; LIFARIZINE; LUBELUZOLE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; OMEGA CONOTOXIN MVIIA; REMACEMIDE; SIPATRIGINE; TIRILAZAD;

AGITATION; CELL PROTECTION; CEREBROVASCULAR ACCIDENT; CONFUSION; COST BENEFIT ANALYSIS; DELIRIUM; DRUG COST; DRUG DISTRIBUTION; EUPHORIA; HALLUCINATION; HUMAN; HYPERTENSION; HYPOTENSION; NAUSEA; NEUROPROTECTION; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PRIORITY JOURNAL; RABBIT; SEDATION; SHORT SURVEY; VOMITING;

BRAIN DAMAGE, CHRONIC; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CEREBRAL INFARCTION; CLINICAL TRIALS; EXCITATORY AMINO ACID ANTAGONISTS; FREE RADICAL SCAVENGERS; HUMANS; REACTIVE OXYGEN SPECIES; RECEPTORS, N-METHYL-D-ASPARTATE; TREATMENT OUTCOME;

EID: 0030023484     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000117208     Document Type: Article

References (12)

1. Lipton SA: Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci 1993;16:527-532.
2. Scatton B, Carter C, Benavides J, Giroux C: N-methyl-D-aspartate receptor antagonists: A novel therapeutic perspective for the treatment of ischemic brain injury. Ccrebrovasc Dis 1991;1:121-135.
3. Touzani O, Young AR, MacKcnzic ET: The window of therapeutic opportunity following focal cerebral ischemia: in Krieglstcin J. Ober-pichler-Schwenk (eds): Pharmacology of Cerebral Ischemia 1994. Stuttgart. Wissenschafl-liche Verlagsgesellschaft. pp 575-588.
4. Muir KW, Grosset DG, Gamzu E, Lees KR: Pharmacological effects of the non-compctitivc NMDA antagonist CNS-1102 in normal volunteers. Br J Clin Pharmacol 1994:38:33-38.
5. Scatton B. Giroux C. Thenot JP, Frost J, George P, Carter C, Benavides J: Eliprodil hydrochloride. Drugs Future 1994; 19:905-909.
6. The STIPAS Investigators: Safety study of tiri-lazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994:25:418-423.
7. Orgogozo JM: Evaluation of treatments in ischaemic stroke patients: in Amery WK. Bousser MG. Rose FC (eds): Clinical Trial Methodology in Stroke. London. Bailliere Tindall, 1990. pp 35-53.
8. Marchal G. Serrati C. Rioux P. Pelit-Taboue MC, Viader F. De la Sayctte V, Lc Doze F. Lochon P. Derlon JM, Orgogozo JM, Baron JC: PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: Relation to outcome. Lancet 1993:341:925-927.
9. Fischer M. Bogousslavsky J: Evolving toward effective therapy for acute ischemic stroke. JAMA 1993;270:360-364.
10. Grotla J: Safety and tolerability of the glutamate antagonist C'GS 19755 in acute stroke patients. Stroke 1994:25:255.
11. Fischer M: Cercstat (CNS 1102) a non-compet-itivc NMDA antagonist in ischemic stroke patients: dose-escalating safety study. Cerebro-vasc Dis 1994:4:245.
12. Whitehead J: Application of sequential methods to a phase III clinical trial in stroke. Drug Info J 1993;27:733-740.